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Key messages
What is already known about this subject?
 ► the routine assessment of Patient index Data 3 
(raPiD3) is considered one of the best validated 
patient- reported outcome measures in rheumatoid 
arthritis (ra).
What does this study add?
 ► raPiD3 is poorly associated with Disease activity 
Score in 28 joints that includes the erythrocyte 
sedimentation rate and especially with its objective 
components, swollen joint count and erythrocyte 
sedimentation rate, over time in patients with ra fol-
lowed up in daily practice and stable on treatment.
 ► raPiD3 associates very well with the subjective 
components of Disease activity Score in 28 joints, 
tender joint count and patient global assessment, 
which confirms that raPiD3 is strongly driven by 
subjective pain instead of inflammatory disease 
activity.
How might this impact on clinical practice?
 ► raPiD3 alone is insufficient to capture objective 
signs of inflammation in routine- care patients with 
ra.
 ► the sole use of subjective patient monitoring in-
struments can be misleading and potentially lead to 
overtreatment of patients with ra, especially in the 
absence of convincing signs of inflammation.
AbstrAct
Objective to test the longitudinal association between 
patient- reported outcome, routine assessment of Patient 
index Data 3 (raPiD3) and the Disease activity Score in 
28 joints that includes the erythrocyte sedimentation rate 
(DaS28- eSr) in routine- care patients with rheumatoid 
arthritis (ra).
Methods Patients with ra treated with disease- modifying 
antirheumatic drugs were included in this prospective 
observational cohort. the longitudinal association 
between raPiD3 (0–10) and DaS28- eSr and its individual 
components (swollen joint count (SJc), erythrocyte 
sedimentation rate (eSr) (mm/hour), tender joint count 
(tJc) and patient global assessment (Pga)) was tested 
using generalised estimating equations in patients with 
more than two consecutive visits with data on raPiD3 
and DaS28- eSr. interactions between raPiD3 and 
gender, pain, Pga and age at baseline were tested, and if 
significant (p<0.20) and clinically relevant, models were fit 
in the corresponding strata.
Results in total, 330 patients were included (mean 
follow- up 10.7 (SD 9.7) months, female gender 67.9%). 
the longitudinal association between raPiD3 and DaS28- 
eSr was weak (β=0.29 (95% ci 0.24 to 0.35), n=207), 
meaning that one unit increase in raPiD3 corresponded 
to a 0.29 unit increase in Disease activity Score in 28 
joints (DaS28). raPiD3 was most strongly associated 
with subjective (tJc: β=0.89 (95% ci 0.61 to 1.17); Pga: 
β=0.94 (95% ci 0.84 to 1.04)) and not with objective 
components of DaS28 (SJc: β=0.29 (95% ci 0.17 to 0.41), 
n=172). the association between raPiD3 and eSr was 
poor but modified by gender, being only significant in men 
(β=0.37 (95% ci 0.08 to 0.67)).
Conclusions these data suggest that raPiD3 does not 
sufficiently capture changes in objective inflammatory 
signs. Monitoring by raPiD3 alone is therefore insufficient 
to follow disease activity in patients wth ra in clinical 
practice.
InTROduCTIOn
Patient- reported outcome measures 
(PROMs) yield clinically important informa-
tion and have been used for many years in the 
development and evaluation of medical inter-
ventions.1–4 These measures primarily aim at 
reflecting patients’ unique perspectives and, 
as such, can contribute to engage patients, 
clinicians and other stakeholders (eg, govern-
ment and payers) in judging the relevance 
of treatment effects and the development of 
value- based healthcare.5 6
PROMs have been awarded a prominent 
place in the management of rheumatic and 
musculoskeletal diseases such as rheumatoid 
arthritis (RA). For instance, the patient global 
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assessment (PGA) has been included as one criterion to 
define the American College of Rheumatology (ACR)–
EULAR Boolean definition of remission.3 7 8 Also, both 
ACR and EULAR prescribe the use of patient- driven 
constructs as part of the core set to measure disease 
activity in daily practice as well as clinical research.3 4
One example of a composite disease activity PROM 
is the Routine Assessment of Patient Index Data 3 
(RAPID3), which is considered the best validated PROM 
in RA.9 10 In contrast to the Disease Activity Score in 28 
joints that includes the erythrocyte sedimentation rate 
(DAS28- ESR) and the presence of swelling in 28 joints, 
RAPID3 is solely based on three (subjective) patient- 
reported domains: physical function, pain and PGA. 
Thus, it has been suggested that RAPID3 (similar to 
other PROMs) could mostly translate factors other than 
inflammation, such as fatigue, depression or even symp-
toms driven by comorbidities.11 12 In reality, the question 
if whether or not RAPID3 truly captures inflammation- 
driven disease activity in clinical practice is still unan-
swered.10 If not, this means that if RAPID3 is used to 
guide treatment decisions on drugs mainly targeting 
inflammation, clinicians may expose patients to unneces-
sary risks with only little or no benefit.
We investigate here the longitudinal relationship 
between RAPID3 and DAS28- ESR (including its individual 
components) in patients with RA in order to determine 
RAPID3’s ability to monitor changes in inflammation- 
driven disease activity appropriately.
PaTIenTs and MeTHOds
Patients and study design
Patients with a clinical diagnosis of RA (and fulfilling 
the ACR 1987 classification criteria13) were included in 
this prospective observational study performed in a large 
rheumatology unit in the Netherlands. Patients could 
have been treated with conventional synthetic disease- 
modifying antirheumatic drugs (csDMARDs) and/or 
biological disease- modifying antimodifying antirheu-
matic drugs (bDMARDs) according to their treating 
rheumatologists and were followed up every 3 months 
for a up to 2 years (April 2013–April 2016). All patients 
provided informed consent before inclusion.
data collection and disease scores
Patients’ characteristics, including gender, age and 
disease duration (years), were collected at baseline 
by rheumatologists and research nurses. Measures of 
disease activity (DAS28- ESR and RAPID3), laboratory 
data (erythrocyte sedimentation rate (ESR)) and medi-
cation status (bDMARD and/or csDMARD, yes/no) 
were assessed every 3 months. RAPID3 is composed of 
three domains: physical function (0–10), pain (Visual 
Analogue Scale 0–10) and PGA of disease activity (0–10).9 
The sum of the three domains is expressed as a contin-
uous total score (range from 0 (best) to 30 (worst)). To 
facilitate comparison with DAS28- ESR, we converted the 
total score to a 0–10 scale in accordance with the RAPID3 
score template.9 The total DAS28- ESR (range: 0–9.3)14 
was computed with four variables: tender joint count 
(TJC 0–28), swollen joint count (SJC 0–28), PGA (0–10) 
and ESR.
statistical analysis
First, we used generalised estimating equations (GEEs), 
with time as the explanatory variable of interest, to 
assess how RAPID3 and Disease Activity Score in 28 
joints (DAS28) changed over time (in separate models). 
Different transformations of time were tested to assess 
which yielded the best fit (assessed by the quasi- likelihood 
under the independence model criterion). A non- linear 
model was chosen if best fitting the data and if the non- 
linear factor (eg, quadratic term) was statistically signifi-
cant (p<0.05).
Second, the longitudinal association between RAPID3 
(explanatory variable) and DAS28- ESR (main outcome) 
was tested in GEE models with autoregression (ie, 
adjusting for the outcome in t-1). The association 
between RAPID3 and each individual component of 
DAS28 (SJC, ESR, TJC and PGA) was also tested in sepa-
rate GEE models. GEE models with autoregression allow 
for a truly longitudinal interpretation of the association 
of interest by ‘isolating’ the within- subject effect while 
correcting for the inherent correlation by specifying a 
‘working correlation matrix’. The exchangeable correla-
tion matrix was used since it proved to better fit the data. 
Interactions between RAPID3 and gender, pain, PGA and 
age were tested, and if statistically significant (p<0.20) 
and clinically relevant, the association of interest was 
tested in stratified models (median value at baseline for 
continuous variables). In all models, only patients with 
data on the outcome and explanatory variable available 
in at least two consecutive visits were included (details on 
statistical analysis available in online supplementary text 
S1). All analyses were performed in STATA V.15.1).
ResulTs
In total, 330 patients (1348 visits; mean 4.0 (SD 2.7) 
number of visits, mean 10.7 (SD 9.7) months of follow- up) 
were included. Baseline characteristics, disease activity 
parameters and treatment status are shown in table 1.
In our population, both DAS28 and RAPID3 had 
shown very limited change over time following a linear 
distribution. On average, DAS28 decreased 0.02 units per 
month (β=−0.02 (95% CI −0.02 to −0.01)), while RAPID3 
increased 0.01 units (β=0.01 (95% CI 0.00 to 0.01)).
longitudinal association between RaPId3 and das28
There was a weak but statistically significant longitu-
dinal association between RAPID3 and DAS28- ESR 
(β=0.29 (95% CI 0.24 to 0.35), n=207). This means that 
1 unit increase in RAPID3 corresponded to only 0.29 
unit increase in DAS28 over time (figure 1). The asso-
ciation between RAPID3 and DAS28 individual compo-
nents (n=172) yielded different results for subjective 
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Table 1 Baseline characteristics of included patients
Parameter
Patients with 
RA (N=330)
Female gender, n (%) 224 (67.9)
Age (years), mean (SD) 62.0 (11.6)
Disease duration, mean (SD) 11.2 (9.6)
DAS28- ESR,* mean (SD) 3.3 (1.4)
SJC (0–28),† mean (SD) 2.3 (3.5)
TJC (0–28),† mean (SD) 4.1 (5.5)
ESR (mm/hour),† mean (SD) 18.7 (17.6)
RAPID3 total score (0–10),‡§ mean (SD) 3.8 (2.1)
RAPID3 function (0–10), mean (SD) 2.5 (1.9)
RAPID3 VAS pain (0–10), mean (SD) 4.3 (2.6)
RAPID3 PGA (0–10), mean (SD) 4.7 (2.4)
Treatment status
  bDMARD only,¶ n(%) 155 (47)
  MTX only, n (%) 77 (23.3)
  bDMARD plus MTX, n (%) 71 (21.5)
  No bDMARD**/MTX, n (%) 27 (8.2)
*DAS28- ESR (four variables, ESR- based).
†N=213.
‡RAPID3 (functioning, VAS pain and PGA).
§RAPID3 0–30 was converted to a 0–10 scale; high numbers 
reflect bad scores.
¶bDMARD includes TNFi (81.9%; etanercept, infliximab, 
adalimumab, certolizumab–pegol and golimumab) and no TNFi 
(18.1%; rituximab, abatacept and tocilizumab).
**Patients (n=27) neither on bDMARDs nor on MTX were treated 
with leflunomide, sulfasalazine or hydroxychloroquine.
bDMARD, biological disease- modifying antirheumatic drug; 
DAS28- ESR, Disease Activity Score in 28 joints that includes the 
erythrocyte sedimentation rate; ESR, erythrocyte sedimentation 
rate; MTX, methotrexate; PGA, patient global assessment; RA, 
rheumatoid arthritis; RAPID3, Routine Assessment of Patient Index 
Data 3; SJC, swollen joint count; TJC, tender joint count; TNFi, 
tumor necrosis factor inhibitor; VAS, Visual Analogue Scale.
Figure 1 Longitudinal association between RAPID3 and 
DAS28- ESR over time (N=207). Longitudinal GEE model with 
autoregression. RAPID3 0–30 converted to a 0–10 scale; 
high numbers reflect worse outcome. RAPID3 domains: 
functioning, pain and patient global assessment; DAS28 (four 
variables, erythrocyte sedimentation rate- based). DAS28, 
Disease Activity Score in 28 joints; DAS28- ESR, Disease 
Activity Score in 28 joints that includes the erythrocyte 
sedimentation rate; GEE, generalised estimating equation; 
RAPID3, Routine Assessment of Patient Index Data 3.
and objective domains (table 2). The difference in the 
numbers of patients included between models with 
DAS28 and models with individual components stems 
from the fact that the individual components of DAS28 
were not available to all patients, although the overall 
score was.
RAPID3 was found to be strongly associated with 
the TJC (β=0.89 (95% CI 0.61 to 1.17)) and with PGA 
(β=0.94 (95% CI 0.84 to 1.04)). This means that 1 unit 
increase in RAPID3 corresponds to almost 1 unit increase 
of PGA. In comparison, the association between RAPID3 
and the SJC was weak at best (β=0.29 (95% CI 0.17 to 
0.41)). Only the association between RAPID3 and ESR 
was modified by gender (interaction p value of 0.141). It 
was somewhat stronger in men (β=0.37 (95% CI 0.08 to 
0.67)) than in women (β=−0.03 (95% CI −0.47 to 0.41)). 
No other significant interactions were found.
dIsCussIOn
In this prospective observational study, we have shown 
that RAPID3 is poorly associated with DAS28- ESR over 
time in patients with RA followed in daily practice. This 
is mainly due to the weak association between RAPID3 
and the objective components of DAS28 (SJC and ESR), 
while RAPID3 associates very well with DAS28 subjective 
components (TJC and PGA).
The association between RAPID3 and DAS28, including 
the individual components of DAS28, have been previ-
ously investigated but, thus far, only in cross- sectional 
observational studies.15–17 Our findings are mostly in line 
with these studies, which have shown a weak to moderate 
association between the two scores. Our study adds to 
the existing literature by showing that this association 
is also absent in a longitudinal setting, thus increasing 
internal validity, and in patients followed up in routine 
clinical practice (external validity). Despite the lack of 
association between RAPID3 and DAS28 in observational 
studies, RAPID3 and other PROMs have been consistently 
shown to discriminate well regarding responses between 
active treatment and placebo in randomised clinical trials 
(RCTs).18 19 Although these data strongly argue in favour 
of PROMs to detect treatment effects in trials, these do 
not necessarily support their use in daily clinical practice. 
In fact, we have recently shown, using data from the same 
cohort, that patients treated with both bDMARDs and 
methotrexate did not have different RAPID3 scores over 
time compared with those on bDMARDs alone, while 
a difference could have been clearly seen with DAS28 
(especially with SJC).11 20
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Table 2 Longitudinal association between RAPID3 (0–10) and DAS28- ESR, including individual components
Outcome DAS28 β (95% CI)†‡ SJC β (95% CI)§ TJC β (95% CI)§ PGA β (95% CI)§ ESR β (95% CI)§
Male (n=52) Female (n=122)
RAPID3* (0–10) 0.29 (0.24 to 0.35) 0.29 (0.17 to 0.41) 0.89 (0.61 to 1.17) 0.94 (0.84 to 1.04) 0.37 (0.08 to 0.67) −0.03 (−0.47 to 0.41)
Statistically significant results are shown in bold.
*RAPID3 domains: functioning, pain and PGA.
†DAS28 (four variables, ESR- based).
‡Models derived from 207 patients.
§Models derived from 172 patients.
DAS28, Disease Activity Score in 28 joints; DAS28- ESR, Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate; ESR, 
erythrocyte sedimentation rate; PGA, patient global assessment; RAPID3, Routine Assessment of Patient Index Data 3; SJC, swollen joint count; 
TJC, tender joint count.
Differences in patients’ characteristics may, at least in 
part, explain why RAPID3 seems to capture treatment 
effects differently in RCTs and observational cohorts. 
RAPID3 mostly relies on subjective assessments of disease 
activity, and these are potentially influenced by comor-
bidities that are less likely to occur in patients selected for 
RCTs. In addition, patients from trials usually have high 
levels of inflammation at study entry. In such setting, 
‘subjective pain’ may be less relevant than ‘inflammatory 
pain’, and outcome measures to quantify disease activity 
will mostly reflect the latter. It should be noted, however, 
that our data stem from a single- centre cohort of patients 
on stable treatment and with limited change in disease 
activity over time. Limited change may preclude subtle 
associations to be detected (eg, between ‘subjective’ and 
‘objective’ pain). Larger studies in patients with higher 
levels of, and most importantly, larger changes in disease 
activity (measured also by scores other than DAS28) 
should give resolution.
Taken all together, these data suggest that RAPID3 is 
most likely not suitable to be used alone for monitoring 
disease activity in patients with RA in daily clinical prac-
tice, since important objective information on the pres-
ence of inflammation (acute phase reactants and swollen 
joints) is missed. For instance, if subjective pain is driving 
high scores in a patient and this leads to treatment inten-
sification (eg, changing or adding disease- modifying anti-
modifying antirheumatic drugs), the end result might be 
‘overtreatment’, which carries negative consequences 
both to the patient and to the society.21 A so- called ‘dual 
strategy’ has been proposed by Ferreira et al,22 which 
defends the use of PROMS as complementary to evaluate 
the global impact of disease beyond inflammatory- driven 
disease activity in order to define additional needs for 
care. This approach still needs to be proven in practice.
In conclusion, our results show that DAS28 and RAPID3 
do not associate with each other in patients with RA 
from daily clinical practice. RAPID3 is strongly driven by 
(subjective) ‘pain’, and its sole use as a monitoring instru-
ment to guide treatment decisions can be misleading and 
potentially harmful to patients.
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